| Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation JK Litton, HS Rugo, J Ettl, SA Hurvitz, A Gonçalves, KH Lee, ... New England Journal of Medicine 379 (8), 753-763, 2018 | 1845 | 2018 |
| PD-L1 expression in triple-negative breast cancer EA Mittendorf, AV Philips, F Meric-Bernstam, N Qiao, Y Wu, S Harrington, ... Cancer immunology research 2 (4), 361-370, 2014 | 1330 | 2014 |
| Breast cancer before age 40 years CK Anders, R Johnson, J Litton, M Phillips, A Bleyer Seminars in oncology 36 (3), 237-249, 2009 | 1000 | 2009 |
| PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression S Jiao, W Xia, H Yamaguchi, Y Wei, MK Chen, JM Hsu, JL Hsu, WH Yu, ... Clinical Cancer Research 23 (14), 3711-3720, 2017 | 863 | 2017 |
| Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer AM Gonzalez-Angulo, KM Timms, S Liu, H Chen, JK Litton, J Potter, ... Clinical Cancer Research 17 (5), 1082-1089, 2011 | 731 | 2011 |
| High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types DJ McGrail, PG Pilié, NU Rashid, L Voorwerk, M Slagter, M Kok, ... Annals of Oncology 32 (5), 661-672, 2021 | 702 | 2021 |
| Genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN clinical practice guidelines in oncology MB Daly, T Pal, MP Berry, SS Buys, P Dickson, SM Domchek, ... Journal of the National Comprehensive Cancer Network 19 (1), 77-102, 2021 | 625 | 2021 |
| Metformin promotes antitumor immunity via endoplasmic-reticulum-associated degradation of PD-L1 JH Cha, WH Yang, W Xia, Y Wei, LC Chan, SO Lim, CW Li, T Kim, ... Molecular cell 71 (4), 606-620. e7, 2018 | 584 | 2018 |
| Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian J Mersch, MA Jackson, M Park, D Nebgen, SK Peterson, C Singletary, ... Cancer 121 (2), 269-275, 2015 | 581 | 2015 |
| Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial F André, R O'Regan, M Ozguroglu, M Toi, B Xu, G Jerusalem, N Masuda, ... The lancet oncology 15 (6), 580-591, 2014 | 570 | 2014 |
| High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2–positive, node-negative tumors 1 cm or smaller AM Gonzalez-Angulo, JK Litton, KR Broglio, F Meric-Bernstam, R Rakkhit, ... Journal of clinical oncology 27 (34), 5700, 2009 | 554 | 2009 |
| NCCN guidelines insights: genetic/familial high-risk assessment: breast and ovarian, version 2.2017 MB Daly, R Pilarski, M Berry, SS Buys, M Farmer, S Friedman, JE Garber, ... Journal of the National Comprehensive Cancer Network 15 (1), 9-20, 2017 | 507 | 2017 |
| Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer S Yennurajalingam, S Frisbee-Hume, JL Palmer, MO Delgado-Guay, ... Journal of Clinical Oncology 31 (25), 3076-3082, 2013 | 393 | 2013 |
| NCCN guidelines insights: genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 1.2020: featured updates to the NCCN guidelines MB Daly, R Pilarski, MB Yurgelun, MP Berry, SS Buys, P Dickson, ... Journal of the National Comprehensive Cancer Network 18 (4), 380-391, 2020 | 372* | 2020 |
| Genetic/familial high-risk assessment: breast and ovarian MB Daly, JE Axilbund, S Buys, B Crawford, CD Farrell, S Friedman, ... Journal of the National Comprehensive Cancer Network 8 (5), 562-594, 2010 | 352 | 2010 |
| Current landscape of immunotherapy in breast cancer: a review S Adams, ME Gatti-Mays, K Kalinsky, LA Korde, E Sharon, ... JAMA oncology 5 (8), 1205-1214, 2019 | 332 | 2019 |
| Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial JK Litton, SA Hurvitz, LA Mina, HS Rugo, KH Lee, A Gonçalves, S Diab, ... Annals of Oncology 31 (11), 1526-1535, 2020 | 277 | 2020 |
| Management of hereditary breast cancer: American society of clinical oncology, American society for radiation oncology, and society of surgical oncology guideline NM Tung, JC Boughey, LJ Pierce, ME Robson, I Bedrosian, JR Dietz, ... Journal of clinical oncology 38 (18), 2080-2106, 2020 | 260 | 2020 |
| PD-L1 expression in triple-negative breast cancer. Cancer Immunol. Res. 2014; 2: 361–370. doi: 10.1158/2326-6066 EA Mittendorf, AV Philips, F Meric-Bernstam, N Qiao, Y Wu, S Harrington, ... CIR-13-0127.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0 | 241 | |
| Effect of metformin on survival outcomes in diabetic patients with triple receptor‐negative breast cancer S Bayraktar, LF Hernadez‐Aya, X Lei, F Meric‐Bernstam, JK Litton, L Hsu, ... Cancer 118 (5), 1202-1211, 2012 | 221 | 2012 |
